ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has
received further clinical testing results from BioScience Laboratories, Inc. for
the T36(R) formulation ("T36(R)"). Complete efficacy was achieved against
Mycobacterium avium and Mycobacterium terrae by T36(R) within 5 minutes, the
shortest time required by the FDA, Health Canada and the European Medicines
Agency ("EMA"). Mycobacteria are the most difficult bacteria to kill and are
used as benchmark organisms to test the effectiveness of anti-microbial
formulations.


Dr. Terrance Owen, President & CEO, states, "Mycobacteria are the 'gold
standard' for anti-bacterial tests. Having successfully passed these tests
required by the FDA, Health Canada and the EMA puts us one step closer to
meetings with these agencies to determine exactly what further testing, if any,
is required to start human trials of the T36(R) formulation."


About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived
from its patented T36(R) technology. The company trades on the TSX Venture
Exchange under the symbol APH.
Emera (TSX:EMA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Emera
Emera (TSX:EMA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Emera